SCHEMBL16636149

SCHEMBL16636149

COC(=O)[C@@H]1CC2CC2C[C@H]1c1csc(-c2cncc(F)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.36
PIK3CG P48736 1/20 0.32
ABL1 P00519 1/20 0.32
DYRK1A Q13627 2/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
KDM4E B2RXH2 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GSK3B P49841 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
NTMT1 Q9BV86 1/20 0.30
TP53 P04637 2/20 0.30
LMNA P02545 1/20 0.30
POLQ O75417 1/20 0.30
IRAK4 Q9NWZ3 1/20 0.30
CYP19A1 P11511 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635736 0.87 KDM4E (0.36) PIM1ABL1KDM4ESMN1; SMN2LMNA
SCHEMBL16636146 0.74 PIM1 (0.35) PIM1ABL1KDM4ESMN1; SMN2
SCHEMBL16636348 0.73 PIM1 (0.37) PIM1ABL1KDM4ESMN1; SMN2LMNA
SCHEMBL16635865 0.71 CTSK (0.47) PIM1PIK3CGDYRK1AGSK3B
SCHEMBL16635866 0.71 CTSK (0.41) PIM1PIK3CGDYRK1AGSK3B
SCHEMBL16638095 0.69 CTSK (0.35) PIM1DYRK1AGSK3BCYP11B1CYP11B2
SCHEMBL16635781 0.69 SLC6A2 (0.46) NTMT1TP53LMNA
SCHEMBL16635783 0.69 SLC6A2 (0.46) NTMT1TP53LMNA
SCHEMBL16636403 0.69 PIM1 (0.34) PIM1PIK3CGABL1DYRK1AGSK3B
SCHEMBL16636405 0.69 PIM1 (0.34) PIM1PIK3CGABL1DYRK1AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ PIM1 2205/4885PIK3CG 3238/4885ABL1 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.